WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

New ATC

 List of new DDDs decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDDs will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list. 

Please note that the list does not include new ATC codes established as a result of ATC alterations.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code Implementation in the ATC/DDD index
A02BX14rebamipide01.02.20172018
A10AE54insulin glargine and lixisenatide01.02.20172018
A10BJ06semaglutide01.02.20172018
A16AB15velmanase alfa01.02.20172018
A16AB16idursulfase beta01.02.20172018
A16AB17cerliponase alfa01.02.20172018
A16AX14migalastat01.02.20172018
C09BX03ramipril, amlodipine and hydrochlorothiazide01.02.20172018
C10BX13rosuvastatin, perindopril and indapamide01.02.20172018
C10BX14rosuvastatin, amlodipine and perindopril01.02.20172018
D06AX14ozenoxacin01.02.20172018
D11AH05dupilumab01.02.20172018
J05AX69 1)sofosbuvir and velpatasvir01.02.20172018
J06BB22obiltoxaximab01.02.20172018
J07BK03zoster, purified antigen01.02.20172018
L01XC27olaratumab01.02.20172018
L01XD07padeliporfin01.02.20172018
L01XE41binimetinib01.02.20172018
L01XE42ribociclib01.02.20172018
L01XE43brigatinib01.02.20172018
L01XX54niraparib01.02.20172018
L01XX55rucaparib01.02.20172018
L01XX56etirinotecan pegol01.02.20172018
L01XX57plitidepsin01.02.20172018
L03AA17pegteograstim01.02.20172018
M05BX06romosozumab01.02.20172018
M09AX06eteplirsen01.02.20172018
N01BA53tetracaine, combinations01.02.20172018
N02AA53hydromorphone and naloxone01.02.20172018
N04BX04opicapone01.02.20172018
N05BX05Lavandulae aetheroleum01.02.20172018
N05CM19suvorexant01.02.20172018
R03DA12mepyramine theophyllinacetate01.02.20172018
R03DX10benralizumab01.02.20172018
S01EX05netarsudil01.02.20172018
V03AE10sodium zirconium cyclosilicate01.02.20172018
V10XX04lutetium (177Lu) oxodotreotide01.02.20172018
1) Temporary code in J05AX69 will be changed to J05AP55 in connection with the implementation of the proposed new ATC 4th level Antivirals for treatment of HCV infections in 2018.

New ATC level codes (other than 5th levels)

ATC codeATC level nameDeadline for objection to temporary alterations Implementation in ATC/DDD index
J05APAntivirals for treatment of HCV infections01.02.20172018

Last updated: 2016-12-06